Treatment of insect bite hypersensitivity
The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of insect bite hypersensitivity of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating insect bite hypersensitivity of equine mammals, preferably of horses.
1. A composition comprising:
(a) a core particle with at least one first attachment site; and
(b) at least one antigen with at least one second attachment site, wherein said at least one antigen is an equine Interleukin-5 antigen (eIL-5 antigen), wherein said eIL-5 antigen comprises a protein with an amino acid sequence of at least 92% amino acid sequence identity with SEQ ID NO:1;
wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.
2. The composition of claim 1 , wherein said protein with an amino acid sequence of at least 92% amino acid sequence identity with SEQ ID NO:1 is selected from SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37 and SEQ ID NO:38.
3. The composition of claim 1 , wherein said core particle is a virus-like particle (VLP).
4. The composition of claim 3 , wherein said VLP is derived from a plant virus or is a VLP of an RNA bacteriophage.
5. The composition of claim 3 , wherein said VLP is a VLP of RNA bacteriophage QB, wherein said VLP of RNA bacteriophage QB comprises recombinant coat proteins, wherein each coat protein SEQ ID NO:31.
6. The composition of claim 3 , wherein said VLP is a modified VLP comprising at least one modified VLP polypeptide, wherein said modified VLP polypeptide comprises
(a) a VLP polypeptide, and
(b) a T helper cell epitope,
wherein said VLP polypeptide comprises
(i) an amino acid sequence of a coat protein of a virus; or
(ii) a mutated amino acid sequence, wherein said mutated amino acid sequence has a sequence identity of at least 90% to said coat protein of a virus.
7. The composition of claim 3 , wherein said VLP is a modified VLP of cucumber mosaic virus (CMV), wherein said modified VLP of CMV comprises at least one modified CMV polypeptide, wherein said modified CMV polypeptide comprises
(a) a CMV polypeptide, and
(b) a T helper cell epitope; and
wherein said CMV polypeptide comprises
(ii) an amino acid sequence of a coat protein of CMV; or
(ii) a mutated amino acid sequence, wherein said mutated amino acid sequence has a sequence identity of at least 90% to said coat protein of CMV.
8. The composition of claim 7 , wherein said T helper cell epitope replaces a N-terminal region of said CMV polypeptide, and wherein said N-terminal region of said CMV polypeptide is amino acids 2-12 of SEQ ID NO:15.
9. The composition of claim 7 , wherein said CMV polypeptide comprises an amino acid sequence of a coat protein of CMV, wherein said amino acid sequence comprises SEQ ID NO:15 or an amino acid sequence having a sequence identity of at least 95% with SEQ ID NO:15; and wherein said CMV polypeptide comprises an amino acid sequence comprising SEQ ID NO:34, and wherein said T helper cell epitope replaces the N-terminal region of said CMV polypeptide, and wherein said replaced N-terminal region of said CMV polypeptide consists of 11 to 13 consecutive amino acids.
10. The composition of claim 7 , wherein said modified CMV polypeptide comprises an amino acid sequence of SEQ ID NO:20 or SEQ ID NO:21.
11. A pharmaceutical composition comprising:
(a) the composition of claim 1 ; and
(b) a pharmaceutically acceptable carrier.
12. The composition of claim 3 , wherein said core particle is a recombinant virus-like particle (VLP).
13. The composition of claim 6 , wherein said VLP polypeptide comprises an amino acid sequence of a coat protein of a plant virus.
14. The composition of claim 9 , wherein said replaced N-terminal region of said CMV polypeptide consists of 11 consecutive amino acids.
15. The composition of claim 14 , wherein said N-terminal region of said CMV polypeptide is amino acids 2-12 of SEQ ID NO:15.
16. The composition of claim 1 , wherein said eIL-5 antigen comprises a protein with an amino acid sequence of at least 95% amino acid sequence identity with SEQ ID NO:1.
17. The composition of claim 1 , wherein said eIL-5 antigen comprises a protein with an amino acid sequence of at least 98% amino acid sequence identity with SEQ ID NO:1.
18. The composition of claim 1 , wherein said protein with an amino acid sequence of at least 92% amino acid sequence identity with SEQ ID NO:1 is selected from SEQ ID NO:2, SEQ ID NO:5 and SEQ ID NO:36.
19. The composition of claim 1 , wherein said eIL-5 antigen comprises a protein with the amino acid sequence SEQ ID NO:2.
20. The composition of claim 1 , wherein said eIL-5 antigen consists of a protein with the amino acid sequence SEQ ID NO:2.
21. The composition of claim 7 , wherein said modified CMV polypeptide comprises the amino acid sequence of SEQ ID NO:20.
22. The composition of claim 19 , wherein said core particle is a modified VLP of cucumber mosaic virus (CMV) comprising modified CMV polypeptides, wherein each of said modified CMV polypeptides comprises the amino acid sequence of SEQ ID NO:20.
23. The composition of claim 20 , wherein said core particle is a modified VLP of cucumber mosaic virus (CMV) comprising modified CMV polypeptides, wherein each of said modified CMV polypeptides comprises the amino acid sequence of SEQ ID NO:20.
24. The composition of claim 1 , wherein said core particle is a modified VLP of cucumber mosaic virus (CMV) comprising modified CMV polypeptides, wherein each of said modified CMV polypeptides comprises the amino acid sequence of SEQ ID NO:20.